ライフサイエンスコーパス: amikacin

1 ient who was in renal failure (8.7 microg/mL amikacin).

2 omoter (kanamycin), and rrs (capreomycin and amikacin).

3 97.4% for capreomycin, and 80% and 100% for amikacin.

4 namycin and those resistant to kanamycin and amikacin.

5 ing of one of the aminoglycoside substrates, amikacin.

6 to cefoxitin, clarithromycin, imipenem, and amikacin.

7 pretive category was lowest for imipenem and amikacin.

8 d by fourfold by day 7 after the addition of amikacin.

9 abscessus clinical strain when combined with amikacin.

10 bited resistance to rifampin, ethambutol, or amikacin.

11 gs included streptomycin, prothionamide, and amikacin.

12 complex with a non-substrate aminoglycoside, amikacin.

13 r for kanamycin; and rrs for capreomycin and amikacin.

14 erapeutic antimicrobials, clarithromycin and amikacin.

15 , linked to high exposure to ceftriaxone and amikacin.

16 ity was poor for vancomycin and was best for amikacin.

17 eta-lactams and close to those observed with amikacin.

18 cs, which usually include co-trimoxazole and amikacin.

19 g combination clarithromycin, cefoxitin, and amikacin.

20 with four that were known to be treated with amikacin.

21 ed killing and the aminoglycoside antibiotic amikacin.

22 o 0.5 mug/ml), ofloxacin (0.25 to 2 mug/ml), amikacin (0.25 to 2 mug/ml), kanamycin (0.25 to 2 mug/ml

23 l injection of ceftazidime (2 mg/0.1 ml) and amikacin (0.4 mg/0.1 ml) was performed without retinecto

24 Intravitreal injections of amikacin (0.4 mg/0.1 mL) were given in 14 of 19 patients

25 or Streptomyces isolates that suggested that amikacin (100% susceptibility for 92 isolates tested) an

26 ities to tested isolates were the following: amikacin (14/16; 87.5%) and clarithromycin (12/16, 75.0%

27 utol, versus 42% for clarithromycin, 19% for amikacin, 18% for rifampicin, and 11% for moxifloxacin.

28 broth macrodilution method were as follows: amikacin, 2 microg/ml; Bay y 3118, 0.015 microg/ml; clar

29 10(6) bacteria for 1 h and then treated with amikacin (200 microg/ml) for 2 h to selectively kill ext

30 within 30 min, which was 8 times faster than amikacin (25 ug/ml or 20x MIC).

31 versus 1 microg/ml), and the aminoglycosides amikacin (32 microg/ml versus 16 microg/ml), gentamicin

32 (P < 0.0001) more likely to be resistant to amikacin (37%, 31/84) than were methicillin-susceptible

33 atments every 8 hrs of gentamicin (80 mg) or amikacin (400 mg) for 14 to 21 days.

34 %); gram-negative bacteria were sensitive to amikacin (5/5, 100%).

35 ated with increased antibiotic resistance to amikacin, 5-fold increase of MIC in 7 out of 8 strains e

36 es were reported to linezolid (45/45; 100%), amikacin (56/57; 98%), trimethoprim-sulfamethoxazole (57

37 istance rates of CRKP isolates were high for amikacin (59.2%) and fluoroquinolones (>97%).

38 in 88.3%, gentamicin 88.8%, ertapenem 91.0%, amikacin 97.5%, and meropenem 98.2%.

39 < .0001), meropenem (94.3%, P < .0001), and amikacin (97.1%, P < .0001).

40 drugs were 99.1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin, and 88.9% for ethionami

41 n, levofloxacin, or moxifloxacin), 99.2% for amikacin, 99.2% for capreomycin, and 96.4% for kanamycin

42 xystreptamine (2-DOS) ring, which may confer amikacin a unique ribosome inhibition profile.

43 ne-third of the isolates were susceptible to amikacin (a very major error).

44 one or in combination with ethionamide (Et), amikacin (A), and Z given for 2 or 7 months.

45 AMR (i.e. a 32-fold increase in MIC) against amikacin, a commonly used treatment for BK.

46 Our findings do not support use of inhaled amikacin adjunctive to standard-of-care intravenous ther

47 We recommend primary testing of amikacin against isolates of the MAC and propose MIC gui

48 A path to continue the effective use of amikacin against resistant infections is to combine it w

49 Amikacin (AK) and colistin (CS) are crucial antibiotics

50 Birds were treated with either Amikacin alone to kill high-frequency hair cells or Amik

51 e voice-recognition system to receive 400 mg amikacin (Amikacin Inhale) or saline placebo, both of wh

52 Amikacin, amikacin and fosfomycin, and amikacin and fosf

53 Resistance to amikacin (AMK) and kanamycin (KAN) in clinical Mycobacte

54 ctions, and showed a synergistic effect with amikacin (AMK) in a mouse model of MDR-Mtb lung infectio

55 ed from endophthalmitis to vancomycin (VAN), amikacin (AMK), and ceftazidime (CEF).

56 ance to INH, the fluoroquinolone (FQ) drugs, amikacin (AMK), and kanamycin (KAN).

57 pDST, and sequencing were >90% for INH, FLQ, amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) r

58 (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) u

59 lates to the following antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanate, ceftriaxo

60 Amikacin, an aminoglycoside antimicrobial agent, was add

61 detection (LOD) of 0.92 ng/mL (1.57 nM) for amikacin and 9.11 pg/mL (7.88 pM) for colistin in blood

62 ely, as well increasing area under curve for amikacin and capreomycin.

63 lin and gentamicin, second-line therapy with amikacin and ceftazidime, and meropenem.

64 us, isolates with constitutive resistance to amikacin and clarithromycin were isolated from several i

65 majority of the isolates were susceptible to amikacin and clarithromycin.

66 lue < 0.001) and 0.7435 (p-value = 0.04) for amikacin and colistin, respectively).

67 quantify and rapidly monitor blood levels of amikacin and colistin.

68 Amikacin, amikacin and fosfomycin, and amikacin and fosfomycin + IV meropenem effectively reduc

69 In particular, IV meropenem and amikacin and fosfomycin + IV meropenem groups presented

70 penem increased in IV meropenem group versus amikacin and fosfomycin + meropenem (p = 0.004).

71 Our findings corroborate that amikacin and fosfomycin alone efficiently reduced P. aer

72 lized amikacin and fosfomycin every 6 hours; amikacin and fosfomycin every 6 hours, with IV meropenem

73 IV meropenem alone every 8 hours; nebulized amikacin and fosfomycin every 6 hours; amikacin and fosf

74 Combination of amikacin and fosfomycin with IV meropenem does not incre

75 ed lower P. aeruginosa concentrations versus amikacin and fosfomycin, amikacin, CONTROL, and fosfomyc

76 Amikacin, amikacin and fosfomycin, and amikacin and fosfomycin + I

77 s observed between HELZJ and the antibiotics amikacin and gentamicin, which resulted in decreased bac

78 utol, amikacin, and linezolid, respectively (amikacin and linezolid indeterminates were higher with F

79 es collected from 413 dogs were analyzed for amikacin and methicillin resistance using broth microdil

80 mino groups of the aminoglycoside antibiotic amikacin and of its acetylated derivatives.

81 ntous cells with cefoxitin and ceftriaxone), amikacin and phages did not modify cell shape but produc

82 timicrobials, the infection was treated with amikacin and polymyxin B-trimethoprim, and the ulcer res

83 n alone to kill high-frequency hair cells or Amikacin and sound exposure to target hair cells across

84 ses Mab persister formation upon exposure to amikacin and the next-generation oxazolidinone tedizolid

85 ect the mechanisms of ribosome inhibition by amikacin and the parent compound, kanamycin.

86 and levofloxacin), and the aminoglycosides (amikacin and tobramycin).IMPORTANCEPseudomonas species o

87 with an intravitreal injection of vancomycin-amikacin and vancomycin-ceftazidime, respectively, which

88 RR) TB with resistance to an aminoglycoside (amikacin) and a fluoroquinolone (ofloxacin).

89 98%) for fluoroquinolones, 64% (45%-80%) for amikacin, and 88% (79%-93%) for ethambutol (specificitie

90 usceptibility to the antibiotics vancomycin, amikacin, and ceftazidime of bacterial endophthalmitis i

91 hthalmitis bacterial isolates to vancomycin, amikacin, and ceftazidime over a 23-year period.

92 0% for all others), followed by doxycycline, amikacin, and ciprofloxacin.

93 tance spread (trimethoprim-sulfamethoxazole, amikacin, and colistin).

94 aterial to antibiotics cefepime, ampicillin, amikacin, and erythromycin was proposed.

95 of susceptibility to gentamicin, tobramycin, amikacin, and erythromycin were obtained for N. nova, N.

96 th phenotypic DST for isoniazid, rifampicin, amikacin, and kanamycin [15/15 (100%)], ethambutol [12/1

97 The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capre

98 /251 (37%) for fluoroquinolones, ethambutol, amikacin, and linezolid, respectively (amikacin and line

99 amic indices for rifampicin, clarithromycin, amikacin, and moxifloxacin are seldom met.

100 cluding gentamicin, streptomycin, kanamycin, amikacin, and paromomycin, have no effect on angiogenin-

101 isolates were susceptible to clarithromycin, amikacin, and rifabutin, while resistance was observed f

102 ible to linezolid, minocycline, tigecycline, amikacin, and tobramycin according to Staphylococcus aur

103 eptible to ampicillin, imipenem, gentamicin, amikacin, and trimethoprim-sulfamethoxazole and had redu

104 Clarithromycin and amikacin are considered cornerstone drugs for MAB treatm

105 The aminoglycosides kanamycin and amikacin are important bactericidal drugs used to treat

106 While macrolides and amikacin are the key drugs in the fight against MAB infe

107 ving azithromycin, ethambutol, rifampin, and amikacin as systemic anti-mycobacterium treatment.

108 t to kanamycin may not be cross-resistant to amikacin, as is often assumed.

109 gs, isoniazid, rifampicin, moxifloxacin, and amikacin, as well as a pan-susceptible wildtype strain.

110 Zn5002 complexes in combination with amikacin at different concentrations completely inhibite

111 Remarkably, combining phage cocktail with amikacin at their sub-inhibitory concentrations produced

112 the average time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxiflo

113 sides, including gentamicin, tobramycin, and amikacin, but they varied in their susceptibility to flu

114 d, pyrazinamide, levofloxacin, moxifloxacin, amikacin, capreomycin and kanamycin resistance produced

115 The four drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide.

116 Amikacin carries the 4-amino-2-hydroxy butyrate (AHB) mo

117 Mycobacterium chelonae) were tested against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxy

118 erium chelonae isolates) were tested against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxy

119 solates to be susceptible or intermediate to amikacin, cefoxitin, imipenem, and the fluoroquinolones

120 otic activity was tested for clarithromycin, amikacin, cefoxitin, tigecycline, and bedaquiline (TMC20

121 +/-1 dilution of the MIC mode) was found for amikacin, ciprofloxacin, clarithromycin, and moxifloxaci

122 Categorical results for amikacin, ciprofloxacin, gatifloxacin, gentamicin, imipe

123 pticum isolates were susceptible in vitro to amikacin, ciprofloxacin, imipenem, linezolid, moxifloxac

124 All isolates were susceptible to amikacin, ciprofloxacin, imipenem, rifampin, trimethopri

125 These results suggest that a combination of amikacin, clarithromycin, and rifabutin may be the most

126 ast one of the three injectable medications: amikacin, clarithromycin, or kanamycin, in addition to i

127 high levels of resistance; susceptibility to amikacin, clarithromycin, tobramycin (only in M. chelona

128 ry 24 hours); and low (<90%) for vancomycin, amikacin, clindamycin, and linezolid.

129 mission, and prior exposure to levofloxacin, amikacin, clindamycin, and meropenem.

130 ophylactic effectiveness of a phage cocktail-amikacin combination as a promising alternative strategy

131 Furthermore, when added to amikacin-containing culture medium in complex to ionopho

132 ncentrations versus amikacin and fosfomycin, amikacin, CONTROL, and fosfomycin groups (p < 0.05), wit

133 e lays the groundwork for rational design of amikacin derivatives with improved antibacterial propert

134 ng activities of six 2-agent combinations of amikacin, doripenem, levofloxacin, and rifampin were qua

135 ambutol, and pyrazinamide, supplemented with amikacin during the first 2 months.

136 n of ETA, in combination with the antibiotic amikacin, enhanced the survival of mice infected with a

137 alation antibiogram (49.6%) and first in the amikacin escalation antibiogram (86.0%).

138 rculosis complex (MTBC) and fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility (the

139 bulized saline solution (CONTROL); nebulized amikacin every 6 hours; nebulized fosfomycin every 6 hou

140 Invasion was quantified by amikacin exclusion assays.

141 ile the sensitivity for fluoroquinolones and amikacin fell below target thresholds, likely due to the

142 trials failed to confirm merits of nebulized amikacin for critically ill patients with nosocomial pne

143 tigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory pu

144 eudomonas aeruginosa pneumonia, resistant to amikacin, fosfomycin, and susceptible to meropenem.

145 with resistance to colistin, carbapenem and amikacin from sewage.

146 etobacter baumannii-calcoaceticus complex to amikacin, gentamicin, and tobramycin using disk diffusio

147 etion of the acrD gene decreased the MICs of amikacin, gentamicin, neomycin, kanamycin, and tobramyci

148 ials considered for plague during pregnancy (amikacin, gentamicin, plazomicin, streptomycin, tobramyc

149 The N3 amino groups of butirosin A and amikacin have lowered pKa values, which is attributed to

150 3 (94%) eyes and intravitreal vancomycin and amikacin in 4 of 63 (6%) eyes.

151 Resistance to amikacin in Gram-negatives is usually mediated by the 6'

152 tra- and inter-ring NOEs for butirosin A and amikacin in their respective ternary complexes with APH(

153 luded cephalosporin, in 576 (70%) cases, and amikacin, in 233 (28%).

154 known antibiotics, fosfomycin, flomoxef and amikacin, in combination as potential antibiotic treatme

155 ligibility and 725 were randomly assigned to Amikacin Inhale (362 patients) or aerosolised placebo (3

156 the efficacy of the combination drug device Amikacin Inhale as an adjunctive therapy to intravenous

157 508 patients (255 in the Amikacin Inhale group and 253 in the placebo group) were

158 at least one dose of study drug (354 in the Amikacin Inhale group and 358 in the placebo group), alt

159 rence in survival: 191 (75%) patients in the Amikacin Inhale group versus 196 (77%) patients in the p

160 erse event (295 [84%] of 353 patients in the Amikacin Inhale group vs 303 [84%] of 359 patients in th

161 ebo group), although one patient assigned to Amikacin Inhale received placebo in error and was includ

162 cognition system to receive 400 mg amikacin (Amikacin Inhale) or saline placebo, both of which were a

163 Amikacin interferes with tRNA translocation, release fac

164 , no mutations were identified in two of the amikacin intermediate-resistant isolates.

165 significantly associated with resistance to amikacin irrespective of methicillin resistance.

166 Amikacin is a first-line treatment for Aeromonas infecti

167 Amikacin is a major drug used for the treatment of Mycob

168 ion or high index of suspicion, intravitreal amikacin is preferred.

169 oniazid, rifampin, streptomycin, ethambutol, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxaci

170 oniazid, rifampin, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxaci

171 lity for phleomycin, bleomycin, capreomycin, amikacin, kanamycin, cetylpyridinium chloride, and sever

172 zid, ethambutol, levofloxacin, moxifloxacin, amikacin, kanamycin, ethionamide, clofazimine, linezolid

173 amycin, a fluoroquinolone, and at least 1 of amikacin, kanamycin, or capreomycin based on drug suscep

174 % confidence interval [CI], 0.84 to 1.0) and amikacin (kappa coefficient, 0.752; 95% confidence inter

175 changes due to adverse events attributed to amikacin, linezolid, or tigecycline.

176 Amikacin liposome inhalation suspension is recommended f

177 moxifloxacin (<=0.5), levofloxacin (<=1.0), amikacin (<=2.0), kanamycin (<=8.0), capreomycin (<=4.0)

178 ts attributed to the additional interactions amikacin makes with the decoding center.

179 or designing inhibitors of the resistance to amikacin mediated by AAC(6')-Ib, an enzyme commonly foun

180 Ten isolates (2.1%) had an initial amikacin MIC of >64 mug/ml, of which seven (1.5%) had MI

181 entration (MIC) <or=40 microg/mL] but not to amikacin (MIC <4 microg/mL).

182 ocycline = doycycline (MIC90, 4 microg/ml) > amikacin (MIC90, 8 microg/ml).

183 This study presents in vitro amikacin MICs for 462 consecutive clinical isolates of t

184 Approximately 50% of isolates had amikacin MICs of 8 mug/ml, and 86% had MICs of </=16 mug

185 -score by 12.54%, 4.61%, 7.45% and 9.58% for amikacin, moxifloxacin, ofloxacin and capreomycin, respe

186 luded, totaling 27 751 prenatal exposures to amikacin (n = 9), gentamicin (n = 345), plazomicin (n =

187 array containing gene aacA4, which codes for amikacin, netilmicin, and tobramycin resistance; a chlor

188 either systemic antibiotics (ceftazidime and amikacin) or no systemic antibiotics.

189 cy records indicated the preferential use of amikacin over other aminoglycosides in the burn intensiv

190 Amikacin plus doripenem was the most effective combinati

191 ng effect in time-kill studies was seen with amikacin plus doripenem.

192 In contrast, amikacin plus levofloxacin was found to be antagonistic

193 (rifamycin, ethambutol, fluoroquinolone, or amikacin) prescribed concomitantly for >28 days.

194 y loads in spleen whereas clarithromycin and amikacin prevented death but had little impact on bacill

195 Amikacin prophylaxis is a useful strategy for preventing

196 Ceftazidime and amikacin provide approximately the same degree of Gram-n

197 isolates that share the property of in vitro amikacin resistance are grouped together by some authors

198 he 422 isolates, 32 that tested positive for amikacin resistance by broth microdilution or disk diffu

199 ions 1375A > G (E. coli 1408A > G) conferred amikacin resistance in four isolates; however, no mutati

200 species and for detecting clarithromycin and amikacin resistance mutations and that it is a useful to

201 Amikacin resistance or intermediate amikacin resistance

202 ethambutol resistance sensitivity, moderate amikacin resistance sensitivity, and promise for linezol

203 Amikacin resistance or intermediate amikacin resistance was detected in 6/26 (23%) isolates.

204 nce in rapid detection of clarithromycin and amikacin resistance was evaluated by comparison with seq

205 Regarding amikacin resistance, NTM-DR detected rrs mutations in fi

206 Amikacin resistance, rare among nocardiae, was observed

207 ecies and for determining clarithromycin and amikacin resistance.

208 Our examination of 13 isolates that are amikacin resistant has revealed the existence of three d

209 2) was tested to assess growth inhibition of amikacin-resistant Acinetobacter baumannii and Klebsiell

210 und hotspots in both percentage and count of amikacin-resistant and ofloxacin-resistant TB.

211 ss the province and in Cape Town, as well as amikacin-resistant and ofloxacin-resistant TB.

212 olates), including 54 clarithromycin- and/or amikacin-resistant strains, were involved.

213 nd 93.7% were susceptible to ceftazidime and amikacin, respectively.

214 100% for capreomycin, and 79.2% and 100% for amikacin, respectively.

215 SMA patient fibroblasts with tobramycin and amikacin resulted in a quantitative increase in SMN-posi

216 to wild-type levels, increased resistance to amikacin returned to wild-type sensitivity, and high lev

217 [95.4-96.8]; specificity 95.0% [94.4-95.7]), amikacin (sensitivity 97.2% [96.4-98.1]; specificity 98.

218 lycosides (kanamycin, gentamycin, sisomycin, amikacin, spectinomycin, neomycin), macrolides-lincosami

219 The TRNOE spectra for amikacin suggest that the 6-amino-6-deoxy-D-glucose ring

220 ubstituents, also acetylated kanamycin A and amikacin that contain a 2'-hydroxyl substituent, althoug

221 For amikacin, the modal MIC for POPA was 2-doubling dilution

222 Amikacin, the semisynthetic derivative of kanamycin, is

223 howed high rates of susceptibility (>95%) to amikacin, tigecycline, and the carbapenems (imipenem and

224 Amikacin, tigecycline, and the carbapenems were active i

225 ted with M.bovis BCG[pMind-Lx], treated with amikacin to kill extracellular bacteria, and then incuba

226 strain of Aeromonas hydrophila resistant to amikacin, tobramycin, and multiple cephalosporins.

227 s induced by the aminoglycosides gentamicin, amikacin, tobramycin, and paromomycin for eight prematur

228 Invasion assays with amikacin treatment demonstrated that nocardiae were inte

229 ith a reduction in the incidence of SSIs was amikacin use as antibiotic prophylaxis.

230 ncentration established for levofloxacin and amikacin was 1.5 microg/ml, that established for capreom

231 ed by our quantitative method, cefepime plus amikacin was found to be the most superior combination,

232 antimicrobial agents except clindamycin and amikacin was significantly reduced.

233 Amikacin was the most active agent against Pseudomonas a

234 The aminoglycoside antibiotic amikacin was used to study the intracellular growth of M

235 methods for a few drugs (e.g., cefoxitin and amikacin) was poor.

236 , ethambutol, and rifamycin, with or without amikacin) was prescribed for 51% of new MAC therapy user

237 ested antimicrobials, except carbapenems and amikacin, was observed in a proportion of hvKP strains,

238 alues of the amino groups of butirosin A and amikacin were determined by 15N NMR spectroscopy.

239 slow effect, both tested phages, as well as amikacin, were able to rapidly abolish the bacterial gro

240 ys showed that the effect of the combination amikacin/Zn5002 was bactericidal.